Wells Fargo & Company MN increased its stake in Castle Biosciences (NASDAQ:CSTL) by 4,164.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 260,513 shares of the company’s stock after purchasing an additional 254,404 shares during the period. Wells Fargo & Company MN owned approximately 1.51% of Castle Biosciences worth $7,766,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of the stock. BlackRock Inc. increased its position in shares of Castle Biosciences by 64.3% in the first quarter. BlackRock Inc. now owns 715,195 shares of the company’s stock worth $21,320,000 after purchasing an additional 280,021 shares during the last quarter. Wasatch Advisors Inc. boosted its stake in Castle Biosciences by 72.7% in the first quarter. Wasatch Advisors Inc. now owns 650,145 shares of the company’s stock worth $19,381,000 after buying an additional 273,778 shares in the last quarter. Driehaus Capital Management LLC boosted its stake in Castle Biosciences by 30.4% in the fourth quarter. Driehaus Capital Management LLC now owns 365,632 shares of the company’s stock worth $12,567,000 after buying an additional 85,231 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Castle Biosciences by 0.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 304,189 shares of the company’s stock worth $10,455,000 after buying an additional 2,467 shares in the last quarter. Finally, Trustcore Financial Services LLC purchased a new stake in Castle Biosciences in the first quarter worth approximately $7,713,000. Institutional investors own 42.74% of the company’s stock.
Shares of CSTL stock opened at $35.09 on Tuesday. The stock has a fifty day moving average of $37.83 and a 200 day moving average of $31.96. Castle Biosciences has a 52 week low of $15.26 and a 52 week high of $44.53. The company has a quick ratio of 7.56, a current ratio of 7.64 and a debt-to-equity ratio of 0.19.
Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.18. Castle Biosciences had a return on equity of 3.88% and a net margin of 11.90%. The company had revenue of $17.42 million during the quarter, compared to analyst estimates of $14.40 million. Equities analysts anticipate that Castle Biosciences will post -0.5 EPS for the current year.
Several analysts have issued reports on CSTL shares. SVB Leerink upped their target price on Castle Biosciences from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 12th. Zacks Investment Research lowered Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 15th. Canaccord Genuity increased their price objective on Castle Biosciences from $41.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. BTIG Research increased their price objective on Castle Biosciences from $32.00 to $41.00 in a research note on Wednesday, March 11th. Finally, Robert W. Baird dropped their price objective on Castle Biosciences from $38.00 to $35.00 and set an “outperform” rating for the company in a research note on Friday, March 27th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Castle Biosciences currently has an average rating of “Buy” and an average price target of $39.00.
In related news, Director Joseph C. Cook III sold 73,944 shares of the firm’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $41.71, for a total value of $3,084,204.24. Following the completion of the sale, the director now owns 212,178 shares of the company’s stock, valued at $8,849,944.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bonnie H. Anderson sold 3,000 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.25, for a total value of $90,750.00. The disclosure for this sale can be found here. Insiders sold 584,087 shares of company stock valued at $22,056,304 in the last ninety days. 39.70% of the stock is currently owned by insiders.
Castle Biosciences Profile
Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.
Read More: Analyst Ratings
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.